Acute dyspnea is a common presentation in emergency departments (EDs), which is one of the main complaints of the patients. There is an urgent need for an effective treatment plan for dyspnea. This study aims to compare the efficacy of inhalant furosemide, oxygen therapy, and placebo in patients with acute dyspnea referred to EDs in Tehran by Emergency Medical Services (EMS). This randomized clinical trial included patients aged 18 to 75 who experienced acute dyspnea and were delivered to the ED by EMS during 2021 and 2022. Participants were randomly assigned to one of three groups: inhalant furosemide, oxygen therapy, or placebo (distilled water) which every group received the medication before entering EDs in a prehospital setting. The mean age of patients was 52.63 ± 20.48 years including 124 women (47.7%) and 136 men (52.3%). Our finding indicates that dyspnea intensity, heart rate, blood pressure, and oxygen saturation showed no significant differences among the groups (p-value). However, these parameters significantly improved in both the treatment and placebo groups (p-value). The mean degree of dyspnea in the furosemide group was lower than that in the other two groups, although the difference was not statistically significant. Hospitalization duration was significantly shorter in the furosemide group compared to the oxygen therapy and placebo groups. Conversely, ICU admission duration was significantly shorter in the oxygen therapy group than in the other two groups. Patient satisfaction levels did not differ significantly across groups. The main effect of inhalant Furosemide in this study was reducing the patient’s length of hospitalization. It seems that Furosemide can have positive effects and can be used as a cure according to its low side effects, also this drug isn’t expensive and its mechanism of action, side effects, and pharmacokinetics have been shown and understood. This study was registered with the IUMS Ethics Committee, receiving the ethical code (IR.IUMS.REC.1399.632), it was also listed in the Iranian Registry of Clinical Trails (IRCT20151003024317N12) on November the 10th, 2020.
26 July 2026 in Endocrinology, Diabetes & Metabolism
Background: Metabolic dysfunction‐associated steatotic liver disease (MASLD) is increasingly prevalent and associated with obesity and dyslipidemia, yet effective pharmacological interventions remain limited. Empagliflozin has shown potential benefits in MASLD, although evidence remains limited. This systematic review and meta‐analysis assesses the efficacy of empagliflozin in patients with MASLD, both diabetic and non‐diabetic. Methods: An advanced database search was conducted up to June 1st, 2026, to identify eligible randomized controlled trials (RCTs). The relevant data were extracted from selected studies. Pooled effect sizes were calculated as weighted mean differences (WMDs) with 95% confidence intervals (CIs) using a random‐effects model. Results: Seven RCTs comprising 591 participants were included. Empagliflozin significantly improved liver enzyme profiles. Specifically, it reduced alanine aminotransferase (ALT) (WMD: −12.24 IU/L; p = 0.037), aspartate aminotransferase (AST) (WMD: −9.51 IU/L; p = 0.048), and gamma‐glutamyl transferase (GGT) (WMD: −14.92 IU/L; p = 0.023). Reductions in alkaline phosphatase (ALP) were observed but did not reach statistical significance (WMD: −26.28 IU/L; p = 0.292). Although substantial heterogeneity was observed for several liver enzyme outcomes. Empagliflozin had no significant effect on lipid parameters, including triglycerides (TG), total cholesterol (TC), low‐density and high‐density lipoprotein cholesterols (LDL‐C, HDL‐C). Empagliflozin also produced a statistically significant but modest reduction in body mass index (BMI) (WMD: −0.71 kg/m 2 ; p < 0.001). Empagliflozin also produced a statistically significant but clinically modest reduction in BMI (WMD: −0.71 kg/m 2 ; 95% CI: −1.00 to −0.43; p < 0.001). Conclusion: Empagliflozin appears to improve liver enzymes and modestly reduce BMI in patients with MASLD, while having a neutral effect on lipid parameters. These findings may confer a statistically significant but clinically modest benefit, particularly in patients with coexisting metabolic risk factors. However, the evidence is limited by small sample sizes, short follow‐up periods, and potential publication bias; therefore, the conclusions should be considered preliminary and hypothesis‐generating.
28 March 2026 in Clinical and Experimental Medicine
Background Accurate pre-operative assessment of axillary lymph node status is key for planning surgeries in early and newly diagnosed breast cancer. Ultrasound (US) and magnetic resonance imaging (MRI) are widely used, but their performance is inconsistent across studies. This meta-analysis evaluates and compares the predictive performance of MRI and US for pre-operative lymph node metastasis in early and newly diagnosed breast cancer. Methods We searched PubMed/MEDLINE, Embase, Scopus, and Web of Science (inception-31 December 2025) for studies on diagnostic performance in preoperative axillary staging using ultrasound and/or MRI. Two independent reviewers extracted or reconstructed true positive, true negative, false positive, false negative, and applied QUADAS-2. Sensitivity and specificity were pooled with random-effects GLMM, with direct comparisons and prevalence-based predictive values. Results Twenty-nine studies (n = 8,544) were included. Pooled sensitivity/specificity were 61.1%/92.0% for MRI and 59.8%/90.3% for ultrasound, yielding LR + 7.64 vs. 6.19 and DOR 18.1 vs. 13.9. HSROC AUCs were 0.863 (MRI) and 0.843 (ultrasound). In paired cohorts (k = 12), sensitivity did not differ, and MRI showed a non-significant specificity advantage. Conclusion MRI and ultrasound showed comparable, moderate sensitivity and high specificity for preoperative axillary metastasis. MRI tended toward higher specificity and positive predictive value, whereas sensitivity did not differ in paired studies. Imaging can guide triage, but histopathology remains necessary for definitive staging.